Amyris to offer $400.0 million of convertible senior notes due 2026

Emeryville, calif., nov. 8, 2021 /prnewswire/ -- amyris, inc. (nasdaq: amrs) ("amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its lab-to-market™ operating platform, today announced that it proposes to offer $400.0 million aggregate principal amount of convertible senior notes due 2026 (the "notes"), subject to market conditions and other factors.
AMRS Ratings Summary
AMRS Quant Ranking